Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Almirall, S.A.    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
10.77(c) 10.78(c) 10.85(c) 10.92(c) 10.92 Last
290 068 483 583 335 667 321 738 169 326 Volume
-0.65% +0.09% +0.65% +0.65% 0.00% Change
More quotes
Financials
Sales 2020 817 M 972 M 972 M
Net income 2020 73,9 M 87,9 M 87,9 M
Net Debt 2020 399 M 475 M 475 M
P/E ratio 2020 24,3x
Yield 2020 1,86%
Sales 2021 887 M 1 055 M 1 055 M
Net income 2021 103 M 123 M 123 M
Net Debt 2021 216 M 257 M 257 M
P/E ratio 2021 18,9x
Yield 2021 1,84%
Capitalization 1 945 M 2 311 M 2 314 M
EV / Sales 2020 2,87x
EV / Sales 2021 2,44x
Nbr of Employees 1 820
Free-Float 40,3%
More Financials
Company
Almirall is Spanish No. 3 in the research, development, manufacturing and marketing of pharmaceutical products primarily intended for treating asthma, chronic obstructive pulmonary disease, psoriasis, rheumatic fever, and multiple sclerosis. Net sales break down by activity as follows: - sale of products (83.9%); - sale of licenses (13%); - other (3.1%): primarily production of medications for third parties. Net... 
More about the company
Notations Surperformance© of Almirall, S.A.
Trading Rating : Investor Rating :
More Ratings
All news about ALMIRALL, S.A.
11/11ALMIRALL S A : Pablo Alvarez appointed to President and GM of Almirall US
PU
11/09ALMIRALL S A : demonstrates resilient performance year to date despite COVID-19 ..
PU
11/09ALMIRALL S A : The Board of Directors nominates Carlos Gallardo as Vice Presiden..
PU
11/09ALMIRALL, S.A. : 3rd quarter results
CO
10/31ALMIRALL S A : First complete dataset in the IL-23p19 class demonstrates ILUMETR..
PU
10/13ALMIRALL S A : announces approval of the reimbursed price for Ilumetri®(tildraki..
PU
10/13ALMIRALL S A : announces approval of the reimbursed pricefor Ilumetri®(tildrakiz..
PU
10/08ALMIRALL S A : and the University of Dundee announce a multi-target research col..
PU
09/28Merck KGaA Appoints New Executive Board Chair, CEO
DJ
09/14ALMIRALL, S.A. : Ex-dividend day for Cash amount paid with the scrip issue offer..
FA
07/27ALMIRALL S A : Spain's Almirall said coronavirus to hit 2020 sales, earnings
RE
07/27ALMIRALL S A : Spain's Almirall said coronavirus to hit 2020 sales, earnings
RE
07/22ALMIRALL S A : joins the AMR Action Fund to support the fight against antimicrob..
PU
07/22ALMIRALL S A : calls for collaborative innovation to advance new treatments for ..
PU
07/10ALMIRALL S A : joins the AMR Action Fund to support the fight against antimicrob..
PU
More news
News in other languages on ALMIRALL, S.A.
11/09ALMIRALL : en forte hausse après ses résultats sur 9 mois
10/13ALMIRALL : remboursement d'Ilumetri approuvé en France
09/28STEFAN OSCHMANN : Merck-Chef Oschmann tritt 2021 ab - Pharmachefin Garijo überni..
08/14TOUR D’HORIZON DES INDICES : Des divergences indicielles
07/29L'ambiance s'alourdit sur les marchés
More news
Analyst Recommendations on ALMIRALL, S.A.
More recommendations
Chart ALMIRALL, S.A.
Duration : Period :
Almirall, S.A. Technical Analysis Chart | ALM | ES0157097017 | MarketScreener
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 15,24 €
Last Close Price 10,92 €
Spread / Highest target 69,4%
Spread / Average Target 39,5%
Spread / Lowest Target -8,42%
EPS Revisions
Managers
NameTitle
Peter Guenter Chief Executive Officer & Director
Jorge Gallardo Ballart Chairman
Eloi Crespo Cervera Senior Vice President-Industrial Operations
Michael McClellan Chief Financial Officer
Bhushan D. Hardas Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.-25.41%2 311
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273